Prostate Cancer Patients May Benefit from Routine Tumor Genetic Testing, Study Suggests

Prostate Cancer Patients May Benefit from Routine Tumor Genetic Testing, Study Suggests
Implementation of routine tumor genetic testing may help identify the approximately 30% of men with metastatic castration-resistant prostate cancer (mCRPC) who may significantly benefit from targeted treatment, namely PARP inhibitors, an international study suggests. The results were presented in a poster, titled “Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study,” at the European Society for Medical Oncology (ESMO) Congress 2019 that recently took place in Barcelona, Spain. Tumors of men with mCRPC can have damaging mutations in a variety of genes, including those involved in the process of homologous recombination (HR) in DNA repair. Among HR gene mutations, those in the BRCA1BRCA2, and ATM genes are the most common, and they have been shown
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *